Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

ead to macular hole, where the traction from the vitreomacular adhesion actually pulls off a piece of the macula (the part of the retina responsible for central vision). If not treated with major eye surgery called a vitrectomy, which involves using suction to remove the vitreous from the eye, macular hole can lead to irreversible, central blindness. While vitrectomy is generally effective in closing macular holes, it is an invasive procedure and a proportion of patients experience side-effects. These include alteration of vision, bleeding, retinal detachment and development of glaucoma and cataracts. Therefore, a nonsurgical treatment option for such patients could be an important breakthrough in the way macular hole patients are treated.

The MIVI-TRUST Program

The microplasmin Phase III program, referred to as MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment), consists of two multi-center, randomized, placebo controlled, double-masked trials. These trials are designed to evaluate a single dose of 125μg microplasmin versus placebo in the intravitreal treatment of patients with symptomatic focal vitreomacular adhesion (VMA). The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion one month after a single injection of microplasmin. This endpoint is assessed using optical coherence tomography (OCT). The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders. In total, over 650 patients were enrolled in these trials, which were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... Aug. 28, 2014 Takeda Pharmaceutical Company ... commitment and submissions of data from a 10-year ... the United States (U.S.) Food and ... and the Japanese Ministry of Health, Labour, and ... Devices Agency (PMDA) for pioglitazone containing medicines, including ...
(Date:8/28/2014)... 28, 2014  In anticipation of the upcoming MEDevice ... available for the first time. Industry Overview: Medtech & ... offers a snapshot of San Diego,s ... from the latest employment statistics to current venture capital investment ... Diego such a vital part of the global ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2
(Date:8/28/2014)... 29, 2014 Top10BestSEOHosting.com has recently ... that FatCow, Hostgator and Bluehost are the best ... ) has been working in the hosting industry ... is connected to multiple GB connections to ensure ... disruptions to customers’ websites. The great thing is ...
(Date:8/28/2014)... August 28, 2014 Blood's Thicker Than Water ... money and family ties in the heart of the city. ... – a story about how disrespect caused two families to ... many streets. , The Yayo Boyz and the M.O.B. Boyz ... speechless and local onlookers in a silent terror. "Guerrilla," AKA ...
(Date:8/28/2014)... Arizona State University graduate student Anthony Gonzales, co-founder ... one of five finalists in Entrepreneur magazine’s 2014 College ... fourth consecutive year that an ASU student has been ... SafeSIPP, and JJ Tang, co-founder of Vantage Realized, were ... dominated the competition: Three of the five finalists were ...
(Date:8/28/2014)... 28, 2014 (HealthDay News) -- Arguments between parents may ... indicates. Parents in more than 200 families were ... At the end of each day, mothers and fathers ... with their children. On days when parents reported ... their children were also strained, according to the study ...
(Date:8/28/2014)... August 28, 2014 ABC television stars ... 49th MDA Show of Strength Telethon airing Sunday, Aug. ... to help raise funds and awareness to help save ... by muscle disease. , Viewers tuning into the 2014 ... heart-felt appeals and introductions from some of the network’s ...
Breaking Medicine News(10 mins):Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... , Isolagen, Inc. Receives Delisting Notice from NYSE Amex , ... Amex: ILE ) today announced that on June ... wholly owned subsidiary, each filed a voluntary petition for reorganization ... the United States Bankruptcy Court for the District of Delaware ...
... ... Connextions and ConnextionsHealth , ... Orlando, FL (Vocus) June 16, 2009 -- Connextions Inc. today announced the appointment ... aspects of the organization,s operational performance, including achievement of key performance metrics for clients; ...
... Rehabilitation Device Enhances Freedom of Motion , , NEW ... rehabilitation patients are learning to correct their unsteady and unsafe gait ... therapeutic device that allows them more freedom of motion to walk ... patients who are unstable or too weak to walk without fear ...
... System Provides Information to Improve Quality of , Programs ... June 16 URAC , the leading ... International , a premier, global, independent accreditor of health ... management professionals. The uSPEQ(R)/URAC Participant Experience Survey for ...
... to begin operations in Seattle , , ... a national carrier of life and disability insurance and ... Administrative Services department in Seattle, Wa. , , ... certain capabilities, technology assets, and employees of a Seattle-based ...
... invasive test might spur more people to be screened, experts ... a less invasive option to colonoscopy, is an effective way ... risk of the disease because of family history or a ... However, the study, in the June 17 issue of the ...
Cached Medicine News:Health News:Isolagen, Inc. Announces Filing of Voluntary Petition Under Chapter 11 of the Bankruptcy Code 2Health News:Isolagen, Inc. Announces Filing of Voluntary Petition Under Chapter 11 of the Bankruptcy Code 3Health News:Connextions Inc. Bolsters Operational Capabilities With Addition Of Senior Business Process Outsouring Professional 2Health News:Connextions Inc. Bolsters Operational Capabilities With Addition Of Senior Business Process Outsouring Professional 3Health News:'Navigaitor' Helps Patients Walk Again 2Health News:'Navigaitor' Helps Patients Walk Again 3Health News:'Navigaitor' Helps Patients Walk Again 4Health News:'Navigaitor' Helps Patients Walk Again 5Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 3Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 4Health News:Assurant Employee Benefits Adds New Voluntary Capabilities 2Health News:For Some, Virtual Colonoscopy May Be Just As Good 2Health News:For Some, Virtual Colonoscopy May Be Just As Good 3
... The ProteomeLab XL-A/XL-I functions over a ... strength and pH, delivering more thorough ... operating methodology measures the relative change ... providing an efficient way to measure ...
For the quantitative determination of triglycerides in serum. Linearity: 1000 mg/dl....
For the direct colorimetric determination of alkaline phosphatase in human serum....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: